Compare Crispr Therapeutics AG (CRSP) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Crispr Therapeutics AG trades at $53.68 (market cap $4.88B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $214.27 (market cap $39.15B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 8× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is more actively traded (2,861,747 versus 2,708,429). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days on average.
| CRSP | TTWO | |
|---|---|---|
Market Cap | $4.88B | $39.15B |
Volume | 2,861,747 | 2,708,429 |
Sector | Health | Technology |
52-Week High | $74.92 | $262.29 |
52-Week Low | $44.34 | $189.69 |
Typical Hold Time | 77 Days | 111 Days |
Enterprise Value | $3.30B | $40.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
Take-Two Interactive (TTWO) trades at $213.88, up 4.84% with bullish technical signals and strong analyst support. The company shows mixed fundamentals with revenue growth to $5.63B but negative net income of -$4.48B, though recent earnings beats and the upcoming GTA VI launch provide optimism. Technical indicators show the stock trading near resistance at $215 with RSI suggesting potential overbought conditions.
The outlook remains positive driven by GTA VI's November launch, with analysts projecting 37% upside to $292.30 consensus target. Key risks include persistent profitability challenges, high debt levels, and execution pressure on major game releases. Institutional ownership trends show continued confidence despite recent financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
